1 Advancing our understanding of skeletal muscle across the lifecourse: protocol for the

2 MASS_Lifecourse study and characteristics of the first 80 participants

3

4 Authors and affiliations

Initials	Surname	Qualification	Affiliations
R M	Dodds	PhD	1,2
С	Hurst	PhD	1,2
S J	Hillman	MSc	1,2
K	Davies	PhD	1
ТЈ	Aspray	MD	1,2
Α	Granic	PhD	1,2
АА	Sayer*	PhD	1,2

5

- AGE Research Group, Newcastle University Institute for Translational and Clinical
 Research, Newcastle upon Tyne, UK
- 8 2. NIHR Newcastle Biomedical Research Centre, Newcastle University and Newcastle upon
- 9 Tyne NHS Foundation Trust, Newcastle upon Tyne, UK
- 10 * Corresponding author:
- 11 Email: <u>avan.sayer@newcastle.ac.uk</u>
- 12 Address: NIHR Newcastle Biomedical Research Centre, 3rd Floor Biomedical Research
- 13 Building, Campus for Ageing and Vitality, Newcastle upon Tyne NE4 5PL, United Kingdom.
- 14 Tel: +44 (0)191 208 1148.

1 Abstract

2 Introduction

3	Sarcopenia, the age-related loss of skeletal muscle strength and mass, carries a significant
4	burden for affected individuals. There has been little investigation of sarcopenia using
5	experimental medicine techniques to study human muscle tissue in detail. The aim of the
6	Muscle Ageing Sarcopenia Studies Lifecourse (MASS_Lifecourse) study is to recruit up to
7	160 participants, equally divided between females and males between ages 45 and 85 years
8	for detailed phenotyping of skeletal muscle health. Here we describe the protocol for the
9	study and the characteristics of the first 80 participants.
10	Methods
11	We are recruiting participants from three sources in the north-east of England. Study
12	fieldwork comprises a home visit (or videocall) for consent and assessment of health,
13	cognition, lifestyle, and wellbeing. This is followed by a visit to a clinical research facility for
14	assessment of sarcopenia status and collection of samples including a vastus lateralis muscle
15	biopsy. We produced descriptive statistics for the first 80 participants, including expressing
16	their grip strength relative to normative data in the form of Z-scores.
17	Results
18	The first 80 participants (53.8% female) covered the target ages, ranging from 48 to 84 years.
19	They were regularly physically active, reported good physical function and had a prevalence
20	sarcopenia (including probable sarcopenia) of 11.3% based on the revised European
21	consensus. Their grip strength was similar to that in the general population, with a mean Z-
22	score of 0.09 standard deviations (95% CI: -1.64, 1.83) above that expected.

1 <u>Conclusions</u>

- 2 The MASS_Lifecourse study combines comprehensive health and lifestyle data with a range
- 3 of biological samples including skeletal muscle. The findings from planned analyses should
- 4 contribute to improvements in the diagnosis, treatment, and prevention of sarcopenia.

1 Introduction

2	Sarcopenia is the loss of muscle strength and mass as we age. It refers specifically to the
3	situation where a person's muscle strength, from tests such as grip strength and five chair
4	stand time, and mass, from measurements such as a dual-energy X-ray absorptiometry (DXA)
5	scanning, are below standard cut-points [1]. The importance of muscle strength and mass is
6	highlighted by the strong evidence that people with lower results for these tests are at greater
7	risk of disability [2], use of social and health care including hospitalisation [3,4] and even all-
8	cause mortality rates [5].
9	
10	There is therefore growing clinical interest in sarcopenia and its potential treatments [6]. A
11	range of mechanisms for sarcopenia have been investigated including mitochondrial
12	dysfunction, anabolic resistance, cellular senescence, motor unit remodelling and oxidative
13	stress [7]. However to date there has been comparatively little investigation of sarcopenia
14	using recent experimental medicine techniques such as the use of 'omics' to study human
15	muscle tissue in detail [8].
16	The prevalence of sarcopenia increases with age, with around one-quarter of those aged 85
17	found to be affected in data from the Newcastle 85+ Study [9]. By this age, it is more likely
18	that sarcopenia will be accompanied by other ageing syndromes such as disability and frailty.
19	This may limit our ability to establish whether changes seen in muscle are due to sarcopenia,
20	as they may reflect both sarcopenia and its associated conditions.
21	
22	An alternative approach is to explore mechanisms of skeletal muscle ageing in the period
23	spanning both mid-life and old age, defined in this study as ages 45-85 years. This will
24	provide opportunities to better understand risk factors and to be able to implement
25	interventions at an earlier stage, analogous to the screening in mid-life that is now established

- 1 for cardiovascular disease risk [10]. An added benefit of recruiting people in this age group
- 2 for detailed assessment of skeletal muscle is that participants who may be eligible for

- 4
- 5 We have previously carried out two pilot Muscle Ageing Sarcopenia Studies (MASS) of
- 6 detailed muscle phenotyping (MASS_Pilot [12] and MASS_PD [13]), and we have built on
- 7 this experience to design the MASS_Lifecourse study. The overall aim of the
- 8 MASS_Lifecourse study is to recruit a sample of up to 160 participants, divided between
- 9 women and men between ages 45 and 85 years for detailed phenotyping of skeletal muscle
- 10 health. In the present paper we describe (i) the protocol for the MASS_Lifecourse study and
- 11 (ii) the characteristics of the first 80 participants.

³ sarcopenia trials can be quickly identified [11].

1 Methods

2 <u>Recruitment</u>

3	We recruited participants from the north-east of England from three different sources. These
4	were: primary care (local GP practices acting as patient identification centres within the
5	North East and North Cumbria Clinical Research Network), secondary care (clinics run
6	within the Newcastle upon Tyne Hospitals NHS Foundation Trust), and the NIHR
7	Bioresource Centre Newcastle (a large panel of individuals who have expressed an interest in
8	taking part in research studies). We started the fieldwork in October 2018, with suspension
9	between March 2020 and September 2020 due to the COVID-19 pandemic.
10	
11	Inclusion and exclusion criteria
12	The inclusion criteria were being aged between 45 and 85 years and having capacity to
13	consent to take part. The exclusion criteria were taking anticoagulant or antiplatelet
14	medications (except for aspirin for primary prevention of cardiovascular disease which could
15	be suspended), diabetes mellitus, immunosuppressant medication, and pregnancy. We also
16	excluded individuals where biopsy of the vastus lateralis muscle was judged not to be feasible
17	by a clinician in the team. Prompts for further assessment by a clinician include a body mass
18	index (BMI) in the obese range, significant mobility limitation or conspicuous superficial
19	veins at the biopsy site. We assessed these criteria throughout the recruitment process to
20	identify at an early stage if a person was not eligible to take part.
21	
22	Ethical approval and informed consent
23	The study was approved by the North East – Newcastle & North Tyneside 1 Research Ethics

- 24 Committee. We obtained informed consent from all participants, including asking if they
- 25 gave permission for biological samples to be used in future collaboration with partners

outside the UK and those in the commercial sector. Consent was rechecked before each part
 of the study.

3

4 <u>Study fieldwork</u>

- 5 The study fieldwork comprised (1) consideration of inclusion and exclusion criteria (as
- 6 above); (2) assessment of health, cognition, lifestyle and wellbeing, carried out either in the
- 7 participant's home or via videocall (with the latter introduced following the COVID-19
- 8 pandemic); followed by a visit to CARU (our Clinical Ageing Research Unit: a clinical
- 9 research facility) for (3) identification of sarcopenia status and other clinical measurements
- 10 and (4) collection of skeletal muscle and other samples. A summary of the fieldwork

11 components is given in Table 1 and full details are provided below.

12

13 Assessment of health, cognition, lifestyle and wellbeing

14 We collected information on health status, including long-term conditions, regular

15 medications, hospital admissions and contact with health and social care professionals. We

16 assessed cognition using the standardized mini-mental state examination (SMMSE) [14] and

17 Montreal cognitive assessment (MoCA) [15]. We assessed smoking history, alcohol intake,

18 and diet using a 20-item food frequency questionnaire [16]. We characterised habitual

19 physical activity in two ways: firstly, using the rapid assessment of physical activity (RAPA)

20 questionnaire [17] and secondly with seven-day accelerometery using a GENEActiv®

21 Original physical activity monitor (ActivInsights Ltd, Cambridge, UK) worn on the dominant

22 wrist at a measurement frequency of 100 Hz.

23

- 24 We asked participants about their educational history (years spent in school and in higher
- education), home and car ownership, and their own and (if relevant) their partner's main

1	occupation classified using the Office for National Statistics (ONS) simplified NS-SEC
2	analytic class [18]. We assessed quality of life using the Short Form 36 (SF-36) questionnaire
3	[19] and mood using the Geriatric Depression Score [20].
4	
5	Assessment of sarcopenia status and other clinical measurements
6	We assessed sarcopenia status using measures recommended in the revised European
7	consensus on the definition and diagnosis of sarcopenia [1]. We assessed self-reported
8	physical function using the SARC-F questionnaire [21]. We measured grip strength (kg) by
9	taking three assessments from each hand using a Jamar dynamometer, with the maximum
10	value used in analyses [22]. We recorded the time take to complete five chair stands [23]. We
11	tested physical performance by measuring normal gait speed over 4 metres and tests of
12	standing balance. We assessed appendicular lean mass using segmental bioimpedance using a
13	Tanita MC-780MA body composition analyser (Tanita Corporation, Arlington Heights, IL,
14	USA), and using DXA (Lunar iDXA, GE Healthcare, USA). Other clinical measurements
15	included height, weight, hip and waist circumference, and lying and standing blood pressure.
16	
17	Collection of skeletal muscle and other samples
18	Participants collected a stool sample at home using the OMNIgene GUT kit (DNA Genotek,
19	Ottawa, Canada) and brought this with them. Once in CARU we collected blood samples
20	after an overnight fast, used to perform a set of routine clinical tests, as well as to provide
21	stored blood for subsequent DNA and RNA extraction and aliquots of serum and plasma.
22	After participants had breakfast, we asked them to provide a urine sample for subsequent
23	metabolomic analyses. At approximately 11am on the day of the CARU visit we performed a
24	biopsy of the vastus lateralis muscle, usually taken on the right side, and using a Weil-

25 Blakesley conchotome [24]. We aimed to collect three muscle samples, with one placed

1	immediately into RNAlater solution (RNAlater TM stabilization solution, Thermofisher
2	Scientific). The other two were placed in gauze prior to processing: one sample orientated
3	and mounted for histology, and then both samples flash frozen in isopentane cooled in liquid
4	nitrogen prior to storage at -80°C [25]. We observed the participant for around two hours
5	following the biopsy procedure and followed-up by telephone the next day and a week later.
6	
7	Data management
8	We stored participants' details in a password-protected database on a secure network drive,
9	accessible only by members of the study team with the required approvals in place. We used
10	a pseudonymised participant identifier throughout the fieldwork. We used double data entry
11	when inputting data from paper forms. We carried out checks for values outside of the
12	feasible range, and we checked the consistency when information was combined from
13	different sources (for example, checking that a participant's weight recorded during a DXA
14	scan was consistent with that from bioimpedance analysis).
15	
16	Maintenance of cohort
17	At the end of the fieldwork, we sought participants' consent to keep them updated on
18	progress with the study and we send an annual newsletter for this purpose. We also sought
19	their permission to contact them about further studies that might be of interest; to date, this
20	has included attending for magnetic resonance imaging of skeletal muscle to assess motor
21	unit function [26].
22	
23	Statistical analyses in this paper
24	In the present paper, we describe the characteristics of the first 80 participants, based on a

25 selection of the variables described under study fieldwork, above, and as shown in Table 2.

From the GeneActiv physical activity monitor recordings we calculated the mean daily
 duration of moderate to vigorous physical activity (MVPA) using the library GGIR [27],
 defined as periods for which measured acceleration was greater than 0.1*g* calculated using the
 Euclidean norm minus one algorithm, and sustained for at least 80% of a minimum bout of 5
 minutes.

6

7 We used the cut-points recommended in the revised European consensus guidelines for 8 diagnosis and severity of sarcopenia [1], classifying participants as having probable 9 sarcopenia (weak grip strength [< 27 kg in males and < 16 kg in females] and/or prolonged 10 time for five chair stands [> 15 seconds]), confirmed sarcopenia if they additionally had low 11 values for appendicular lean mass index (ALMI, appendicular lean mass in kg divided by height-squared [$< 7.0 \text{ kg/m}^2$ in males and $< 5.5 \text{ kg/m}^2$ in females]), and severe sarcopenia if 12 13 they also had slow gait speed (≤ 0.8 m/s). We also compared our grip strength values to 14 published British normative data [28], by expressing each patient's value as a Z-score. Each 15 Z-score is calculated as the patient's grip strength value less the mean expected for their age 16 and sex, divided by the grip strength standard deviation (SD) for their age and sex. Z-scores 17 of +1 and -1 indicate grip strength values one standard deviation above and below, 18 respectively, that expected for age and sex. 19

We produced descriptive statistics stratified by sex, with differences between males and
females analysed using chi-squared tests in the case of categorical variables, and Wilcoxon
rank sum tests for continuous variables. We carried out statistical analysis using R, version
4.0.4 [29].

1 **Results**

2	Here we describe characteristics of the first 80 participants in the MASS_Lifecourse Study
3	who had a home visit and attended the CARU, as shown in Table 2. The participants spanned
4	the intended age range (minimum 48, maximum 84 and median 64 years), with an
5	approximately even split between males (46.2%) and females (53.8%). During this period of
6	fieldwork, we also visited seven potential participants at home and found that they had
7	exclusion criteria that prevented them from taking part. A further five participants had a
8	home visit and were recruited to the study but did not progress to the CARU visit due to a
9	change in their personal circumstances.
10	
11	Assessment of health, cognition, lifestyle and wellbeing
12	The majority (n=45, 56.3%) of participants had two or more long-term condition (i.e. they
13	had multimorbidity), with a tendency for females to have more long-term conditions than
14	males, as shown in Table 2. Participants had normal cognition based on the MoCA test. In
15	terms of lifestyle, most participants undertook regular aerobic activity based on the RAPA1
16	questionnaire, and in keeping with this had evidence of regular moderate-vigorous physical
17	activity based on GENEActiv accelerometry. Most participants did not undertake regular
18	strength and flexibility training as assessed using the RAPA2 questionnaire. Finally, most
19	participants had high self-rated physical function based on the SF-36 questionnaire,
20	especially so in males.
21	
22	Assessment of sarcopenia status and other clinical measurements
23	Most participants did not score any points on the SARC-F questionnaire (n=66, 82.5%) or
24	meet the criteria for the European revised sarcopenia definition, with (n=9, 11.2%) having
25	probable sarcopenia or greater, as shown in Table 2. As expected, we saw stronger average

- 1 grip strength and ALMI in males compared to females. Participants' grip strength Z-score
- 2 values were typically as expected for their age and sex, with a mean Z-score of 0.09 standard
- 3 deviations (95% CI: -1.64, 1.83) above population reference values. Finally, most participants
- 4 had a BMI in the overweight range.

1 Discussion

2 <u>Summary of findings</u>

3	We have successfully established a cohort study that will improve our understanding of
4	changes in skeletal muscle in mid-life and old age, with fieldwork ongoing at the time of
5	writing. The assessments as described in this protocol paper include a comprehensive
6	assessment of a range of health and lifestyle factors, cognition, and sarcopenia status. There
7	is also collection of a range of biological samples including skeletal muscle ready for
8	subsequent analyses including multi-omics. The first 80 participants covered the intended age
9	range (45 to 85 years) and were characterised by having regular physical activity, good self-
10	reported physical function, and low levels of sarcopenia.
11	
12	Interpretation of findings
13	We had a high rate of those who underwent a home visit going on to have assessments in the
14	CARU (87%) as we used initial telephone contact to check exclusion criteria and to check
15	that it was a feasible time to take part in the study. We anticipated a healthy volunteer effect
16	and there was some evidence that the first 80 participants in MASS_Lifecourse were, on
17	average, more active and had better self-reported physical function that the general
18	population. In contrast, we saw levels of muscle strength (assessed by grip strength) which
19	were at the same level as that seen in the general population, and few participants reported
20	undertaking regular strength training.
21	
22	Strengths and limitations
23	A strength of our work is that we used the same recruitment sources to cover the age range
24	from 45 – 85 years, meaning that any age-related differences in muscle characteristics will
25	not have arisen owing to the use of different recruitment strategies in different age groups.

1	There was some evidence of a healthy volunteer effect, and this may have contributed to the
2	low levels of confirmed (or severe) sarcopenia present in the study. This also has the potential
3	to be a strength of this cohort, since it provides an opportunity to gain insights into the
4	biological processes that lead to sarcopenia, and also to understand age-related changes in
5	skeletal muscle (sometimes termed primary sarcopenia) separated as far as possible from
6	muscle changes due to long-term conditions, termed secondary sarcopenia, and an area of
7	growing research interest [1,31].
8	
9	Plans for future research
10	A range of analyses are planned, due to take place following the completion of study
11	fieldwork in 2022 to avoid batch effects. This includes histology, transcriptomics, and
12	proteomics of skeletal muscle. These will complement existing studies in this area but with a
13	larger sample size than available previously [32]. This study protocol also forms a template
14	for future cohort studies, including in people living with specific conditions, or clusters of
15	long-term conditions. The use of such a standardised approach will allow the comparison of
16	findings with data from the present study.
17	
18	Conclusions
19	We have successfully established a cohort study to improve our understanding of changes in
20	skeletal muscle in mid-life and old age. The planned analyses of the samples collected in the
21	MASS_Lifecourse study and their relation to a range of participant characteristics will
22	considerably increase our understanding of the biological mechanisms underpinning age-
23	related muscle loss. This knowledge should in turn lead to improvements in our ability to
24	diagnose, treat and prevent sarcopenia.

1 Declaration of sources of funding

2 AAS is Director of the NIHR Newcastle Biomedical Research Centre.

3

- 4 The research was supported by the National Institute for Health Research (NIHR) Newcastle
- 5 Biomedical Research Centre based at Newcastle upon Tyne Hospitals NHS Foundation Trust
- 6 and Newcastle University. The views expressed are those of the author(s) and not necessarily
- 7 those of the NHS, the NIHR or the Department of Health.

1 **References**

- 2 1. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, et al. Sarcopenia:
- 3 revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31.
- 4 2. den Ouden MEM, Schuurmans MJ, Arts IEMA, van der Schouw YT. Physical
- 5 performance characteristics related to disability in older persons: a systematic review.
- 6 Maturitas. 2011;69(3):208–19.
- 3. Janssen I, Shepard DS, Katzmarzyk PT, Roubenoff R. The healthcare costs of sarcopenia
 in the United States. J. Am. Geriatr. Soc. 2004;52(1):80–5.
- 9 4. Simmonds SJ, Syddall HE, Walsh B, Evandrou M, Dennison EM, Cooper C, et al.
- 10 Understanding NHS hospital admissions in England: linkage of Hospital Episode Statistics to
- 11 the Hertfordshire Cohort Study. Age Ageing. 2014;43(5):653–60.
- 12 5. Cooper R, Kuh D, Hardy R, Mortality Review Group. Objectively measured physical
- 13 capability levels and mortality: systematic review and meta-analysis. BMJ. 2010;341:c4467.
- 14 6. Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet. 2019;393(10191):2636–46.
- 15 7. Aihie Sayer A, Robinson SM, Patel HP, Shavlakadze T, Cooper C, Grounds MD. New
- 16 horizons in the pathogenesis, diagnosis and management of sarcopenia. Age Ageing.
- 17 2013;42(2):145–50.
- 18 8. Morley JE, Anker SD. Myopenia and precision (P4) medicine. J. Cachexia. Sarcopenia19 Muscle. 2017.
- 20 9. Dodds RM, Granic A, Davies K, Kirkwood TBL, Jagger C, Sayer AA. Prevalence and
- incidence of sarcopenia in the very old: findings from the Newcastle 85+ Study. J Cachexia
 Sarcopenia Muscle. 2017;8(2):229–37.
- 23 10. Robson J, Dostal I, Sheikh A, Eldridge S, Madurasinghe V, Griffiths C, et al. The NHS
- Health Check in England : an evaluation of the first 4 years. BMJ Open. 2016;6:e008840.
- 25 11. Band MM, Sumukadas D, Struthers AD, Avenell A, Donnan PT, Kemp PR, et al.
- Leucine and ACE inhibitors as therapies for sarcopenia (LACE trial): study protocol for a randomised controlled trial. Trials. 2018;19(1):6.
- 28 12. Dodds RM, Davies K, Granic A, Hollingsworth KG, Warren C, Gorman G.
- Mitochondrial respiratory chain function and content are preserved in the skeletal muscle of active very old men and women. Exp. Gerontol. 2018;113:80–85.
- 31 13. Yarnall AJ, Granic A, Waite S, Hollingsworth KG, Warren C, Vincent AE, *et al.* The
- 32 feasibility of muscle mitochondrial respiratory chain phenotyping across the cognitive
- 33 spectrum in Parkinson's disease. Exp. Gerontol. 2020;138:110997.
- 14. Molloy DW, Standish TIM. A Guide to the Standardized Mini-Mental State Examination.
 Int. Psychogeriatrics. 1997;9(S1):87–94.
- 36 15. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al.
- 37 The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive
- 38 Impairment. J. Am. Geriatr. Soc. 2005;53(4):695–699.

- 1 16. Topolski TD, LoGerfo J, Patrick DL, Williams B, Walwick J, Patrick MB. The Rapid
- 2 Assessment of Physical Activity (RAPA) among older adults. Prev. Chronic Dis.
- 3 2006;3(4):1–8.
- 4 17. Office of National Statistics. ONS Occupation Coding Tool. 2021. Available at:
- 5 https://onsdigital.github.io/dp-classification-tools/standard-occupational-
- 6 classification/ONS_SOC_occupation_coding_tool.html . Accessed September 2, 2021.
- 7 18. Ware JE, Gandek B. Overview of the SF-36 Health Survey and the International Quality
- 8 of Life Assessment (IQOLA) Project. J. Clin. Epidemiol. 1998;51(11):903–912.
- 9 19. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and
- 10 validation of a geriatric depression screening scale: a preliminary report. J. Psychiatr. Res.
- 11 17(1):37–49.
- 12 20. Malmstrom TK, Miller DK, Simonsick EM, Ferrucci L, Morley JE. SARC-F: A symptom
- 13 score to predict persons with sarcopenia at risk for poor functional outcomes. J. Cachexia.
- 14 Sarcopenia Muscle. 2016;7(1):28–36.
- 15 21. Roberts HC, Denison HJ, Martin HJ, Patel HP, Syddall H, Cooper C, et al. A review of
- 16 the measurement of grip strength in clinical and epidemiological studies: towards a
- 17 standardised approach. Age Ageing. 2011;40(4):423–9.
- 18 22. Dodds RM, Murray JC, Granic A, Hurst C, Uwimpuhwe G, Richardson S, et al.
- 19 Prevalence and factors associated with poor performance in the 5-chair stand test: findings
- 20 from the Cognitive Function and Ageing Study II and proposed Newcastle protocol for use in
- the assessment of sarcopenia. J. Cachexia. Sarcopenia Muscle. 2021;12(2):308–318.
- 22 23. Baczynska AM, Shaw S, Roberts HC, Cooper C, Sayer AA, Patel HP. Human Vastus
- Lateralis Skeletal Muscle Biopsy Using the Weil-Blakesley Conchotome. JoVE J. Vis. Exp. 2016: (March):e52075. doi:10.2701/52075
- 24 2016;(March):e53075, doi:10.3791/53075.
- 24. Meng H, Janssen PML, Grange RW, Yang L, Beggs AH, Swanson LC, *et al.* Tissue
 triage and freezing for models of skeletal muscle disease. J Vis. Exp. 2014;89.
- 25. Tullo E, Dodds RM, Birkbeck M, Habiballa L, Sayer AA. Paving the translational ageing
 research pathway—training the next generation of researchers. Age Ageing. 2020:1–4.
- 26. van Hees VT, Fang Z, Zhao JH, Heywood J, Mirkes E, Sabia S, *et al.* {GGIR}: Raw
 Accelerometer Data Analysis. 2021.
- 31 27. Dodds RM, Syddall HE, Cooper R, Benzeval M, Deary IJ, Dennison EM, et al. Grip
- strength across the life course: normative data from twelve British studies. PLoS One.
 2014;9(12):e113637.
- 28. R Core Team. R: A Language and Environment for Statistical Computing. R Foundation
 for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/. 2021.
- 36 29. St-Jean-Pelletier F, Pion CH, Leduc-Gaudet J-P, Sgarioto N, Zovilé I, Barbat-Artigas S,
- 37 *et al.* The impact of ageing, physical activity, and pre-frailty on skeletal muscle phenotype,
- mitochondrial content, and intramyocellular lipids in men. J. Cachexia. Sarcopenia Muscle.
 2017;8(2):213–228.
- 40 30. Dodds RM, Granic A, Robinson SM, Sayer AA. Sarcopenia, long-term conditions, and

- 1 multimorbidity: findings from UK Biobank participants. J. Cachexia. Sarcopenia Muscle.
- 2 2020;11:62-8.
- 3 31. Tumasian RA, Harish A, Kundu G, Yang JH, Ubaida-Mohien C, Gonzalez-Freire M, et
- 4 *al.* Skeletal muscle transcriptome in healthy aging. Nat. Commun. 2021;12(1).

1 **Table 1: Overview of study fieldwork**

Component	Location	Components
Initial contact to discuss study	Telephone	 Opportunity to raise questions after reading study participant information sheet Assessment of inclusion and exclusion criteria
Assessment of health, cognition, lifestyle and wellbeing	Own home*	 Long-term conditions and medications SMMSE and MoCA Food frequency questionnaire RAPA and GeneActiv 7-day wrist-worn accelerometry Smoking and alcohol Education and occupation Home ownership and number of cars Geriatric depression scale SF-36
Assessment of sarcopenia status	CARU	 SARC-F Hand grip strength Short physical performance battery: chair stand test, gait speed, balance tests Segmental bioimpedance DXA
Other clinical measurements	CARU	Height and weightHip and waist circumferenceLying and standing blood pressure
Collection of skeletal muscle and other samples	CARU	 Vastus lateralis muscle biopsy Blood samples (fasting) Urine sample Collection of stool sample kit

2

3 * With some conducted via videocall from September 2020 onwards.

4 CARU, Clinical Ageing Research Unit. DXA, dual-energy X-ray absorptiometry. MoCA,

5 Montreal cognitive assessment. SF-36, Short Form 36 questionnaire. SMMSE, standardized

6 mini-mental state examination. RAPA, rapid assessment of physical activity questionnaire.

1	Table 2:	Characteristics	of the	e sample,	by	sex
---	----------	-----------------	--------	-----------	----	-----

Characteristic	Males (n=37)	Females (n=43)	<i>P</i> -value*				
Age (years)	65 [59, 73]	61 [56, 69]	0.248				
Age category			0.594				
45-54	5 (13.51)	8 (18.61)					
55-64	13 (35.14)	17 (39.53)					
65-74	14 (37.84)	12 (27.91)					
75-85	5 (13.51)	6 (13.95)					
Assessment of health, cognition, life	style and wellbeing	T	- 1				
No. long term conditions	1 [1,2]	2 [1,3]	0.548				
No. medications	1 [0,2]	1 [1,4]	0.343				
MoCA	27 [26, 28]	27 [25.5, 28]	0.656				
RAPA 1 (aerobic)	6 [6, 7]	6 [6, 6.5]	0.132				
RAPA 2 (strength and flexibility)	0 [0, 2]	1 [0, 3]	0.514				
Daily MVPA (minutes)	32.06 [14.90, 45.85]	20.40 [7.07, 40.33]	0.064				
Smoking history			0.393				
Never	26 (70.27)	25 (58.14)					
Previous	11 (29.73)	17 (39.54)					
Current	0 (0.00)	1 (2.33)					
Accommodation			N/A				
Home-owner	37 (100)	39 (90.7)					
Private / local authority tenant	0 (0.00)	4 (9.30)					
SF-36 general health score	59 [52, 65]	62 [58, 70]	0.046				
SF-36 physical function score	100 [100, 100]	94.44 [88.89, 100]	< 0.001				
Assessment of sarcopenia status and	l other clinical measureme	nts					
SARC-F			N/A				
0	34 (91.89)	32 (74.42)					
1	3 (8.11)	9 (20.93)					
2	0 (0.00)	0 (0.00)					
3	0 (0.00)	1 (2.33)					
4+	0 (0.00)	1 (2.33)					
Revised EWGSOP category			0.608				
None	34 (91.89)	37 (86.05)					
Probable	3 (8.11)	4 (9.30)					
Confirmed	0 (0.00)	1 (2.33)					
Severe	0 (0.00)	1 (2.33)					
Maximum grip strength (kg)	42 [38, 46]	26 [21.5, 30.5]	Not tested				
Maximum grip Z-score	0.27 [-0.31, 0.73]	0.02 [-0.49, 0.56]	0.757				
Chair stand (5) (s)	11.15 [9.81, 13.38]	11.11 [9.6, 12.62]	0.655				
ALMI from DEXA (kg/m ²)	8.29 [7.64, 8.90]	6.21 [5.73, 7.01]	Not tested				
Gait speed (m/s)	1.25 [1.12, 1.32]	1.16 [1.01, 1.26]	0.035				
BMI (kg/m ²)	26.40 [24.75, 28.04]	25.71 [22.96, 27.99]	0.341				
BMI category			0.512				
<25: Normal	11 (29.73)	18 (41.86)					
25-30: Overweight	20 (54.05)	20 (46.51)					
> 30: Obese	6 (16.22)	5 (11.63)					

- 1 Values shown are median [interquartile range] or count (%).
- 2
- 3 ALMI, appendicular lean mass index. BMI, body mass index. DXA, dual-energy X-ray
- 4 absorptiometry. EWGSOP, European Working Group on Sarcopenia in Older People. MoCA,
- 5 Montreal cognitive assessment. SF-36, Short Form 36 questionnaire. RAPA, rapid
- 6 assessment of physical activity questionnaire.
- 7
- 8 * Differences between males and females analysed using chi-squared tests in the case of
- 9 categorical variables and Wilcoxon rank-sum tests for continuous variables. RAPA and
- 10 SARC-F scores, and numbers of long-term conditions and medications have been treated as
- 11 categorical. Yates' continuity correction has been applied to the chi-squared test of SARC-F,
- 12 and continuity correction has also been applied in the Wilcoxon rank sum tests of maximum
- 13 grip strength, MOCA, SF-36 general health and physical function, gait speed and chair stand
- 14 because of ties in the data. Small numbers in some cells meant that a P-value could not
- 15 always be computed, as shown by N/A.